A leading market research firm, has released its highly anticipated report on the pet cancer therapeutics market. The comprehensive study highlights a remarkable compound annual growth rate CAGR 10.5% and a substantial market, US$ 540.11 million by 2030 reinforcing the immense potential of this sector. With a keen focus on innovative treatments and growing pet healthcare awareness, the report offers valuable insights to industry stakeholders, investors, and healthcare professionals, paving the way for future advancements in pet cancer therapeutics.
Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/62
Key Development:
• In March 2019, Pfizer Inc., received FDA approval for the Palladia, the first drug officially approved for the use in treating dog cancer.
• In October 2017, VETCO, launched animal cancer treatment novel drug Antic an in Taiwan. Antic an, the animal cancer treatment novel drug, has been approved by the COA, the Taiwanese Council of Agriculture and is the 3rd approved anticancer drug in global and 1st in Asia.
Analyst view :
According to the report, the pet cancer therapeutics market is poised for substantial expansion in the coming years. Factors such as increasing pet ownership, rising awareness of pet health, and advancements in cancer treatment technologies contribute to the market's positive trajectory. The analysts project a robust compound annual growth rate CAGR 10.5 %and anticipate the market to reach a remarkable value540.11 million by 2030, indicating significant investment potential.
The study also highlights key trends shaping the industry, including the emergence of targeted therapies, personalized treatment options, and the integration of innovative diagnostic techniques. The analysts emphasize the importance of strategic collaborations between pharmaceutical companies, veterinary clinics, and
Research institutions to accelerate the development and commercialization of novel pet cancer therapeutics.
Competitive Analysis:
The key players operating in the global Pet Cancer Therapeutics Market includes Zoetis, VetDC, Inc., BoehingerIngelheim International GmbH, Zenoaq, Aratana Therapeutics, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Oasmia Pharmaceuticals AB, and Rhizen Pharmaceuticals SA.
To know more
Contact Us:
Sales
Prophecy Market Insights
U.S. 1 860 531 2574
Row: 917775049802
Email- [email protected]
Website- www.prophecymarketinsights.com
Blog- www.prophecyjournals.com